24/7 Market News Snapshot 19 February, 2025 – Alzamend Neuro, Inc. Common Stock (NASDAQ:ALZN)

February 19, 2025

DENVER, Colo., 19 February, 2025 (247marketnews.com) – (NASDAQ:ALZN) are discussed in this article.
Alzamend Neuro, Inc. (ALZN) has made significant strides in both market performance and clinical innovation, with notable developments capturing the attention of investors and the medical community. In pre-market trading, ALZN experienced a robust increase, surging 26.85% to reach $1.370 from the previous close of $1.080. The trading volume soared to 6.09 million shares, reflecting heightened investor interest and confidence in the company’s initiatives.

Adding to this momentum, Alzamend recently announced the successful completion of an advanced head coil developed in partnership with Tesla Dynamic Coils BV. This innovative technology is expected to play a pivotal role in the company’s five upcoming Phase II clinical trials, conducted in collaboration with Massachusetts General Hospital. The head coil will facilitate unparalleled whole-brain imaging of lithium, allowing for enhanced resolution and accurate measurement of lithium levels within the brain’s complex structures.

The aim of these studies is to investigate the efficacy and safety profiles of Alzamend’s investigational product, AL001, in comparison to traditional lithium salts. AL001, a transformative lithium-delivery system, is designed to optimize brain absorption while minimizing systemic exposure, thereby reducing typical adverse effects associated with lithium therapies. Early nonclinical studies suggest that AL001 may enhance brain absorption while maintaining lower blood concentration levels than existing treatments, indicating its potential to offer safer and more effective options for patients.

Stephan Jackman, CEO of Alzamend, emphasized the importance of the new head coil, describing it as a significant development that will unveil new insights into lithium’s interaction with the brain. He expressed optimism that this advancement will expedite clinical trial processes and highlight AL001’s potential across various neurodegenerative and psychiatric disorders. Alzamend remains dedicated to pioneering innovative solutions aimed at enhancing patient care and treatment outcomes, with forthcoming updates anticipated as the clinical trials progress.

Related news for (ALZN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.